OBJECTIVE: To determine whether cardiac dimensions were different in girls with Turner syndrome (TS) who received growth hormone (GH) compared with those who did not receive GH. STUDY DESIGN: This retrospective, cross-sectional study analyzed echocardiograms in 86 females with TS divided into GH-treated (n = 67) and untreated (n = 19) groups. The subjects all participated in the National Institutes of Health protocol between 2001 and 2006. RESULTS: The average age was 16.2 years (range, 10 to 25 years), and average duration of GH treatment was 4.4 years (range, 1 to 14 years). The GH-treated group was taller by approximately 7 cm (P = .004), but cardiac dimensions normalized to body surface area (BSA), including septal and posterior wall thickness and left ventricular (LV) mass and internal diameters, did not differ significantly between the 2 groups. The fractional shortening index was similar in the 2 groups. Multiple regression analyses indicated that BSA, but not duration of GH treatment, predicted LV dimensions in girls with TS. CONCLUSIONS: GH treatment of girls with TS increases stature but does not disproportionately affect cardiac dimensions.
OBJECTIVE: To determine whether cardiac dimensions were different in girls with Turner syndrome (TS) who received growth hormone (GH) compared with those who did not receive GH. STUDY DESIGN: This retrospective, cross-sectional study analyzed echocardiograms in 86 females with TS divided into GH-treated (n = 67) and untreated (n = 19) groups. The subjects all participated in the National Institutes of Health protocol between 2001 and 2006. RESULTS: The average age was 16.2 years (range, 10 to 25 years), and average duration of GH treatment was 4.4 years (range, 1 to 14 years). The GH-treated group was taller by approximately 7 cm (P = .004), but cardiac dimensions normalized to body surface area (BSA), including septal and posterior wall thickness and left ventricular (LV) mass and internal diameters, did not differ significantly between the 2 groups. The fractional shortening index was similar in the 2 groups. Multiple regression analyses indicated that BSA, but not duration of GH treatment, predicted LV dimensions in girls with TS. CONCLUSIONS: GH treatment of girls with TS increases stature but does not disproportionately affect cardiac dimensions.
Authors: Yvonne K van Pareren; Sabine M P F de Muinck Keizer-Schrama; Theo Stijnen; Theo C J Sas; Maarten Jansen; Barto J Otten; J J Gera Hoorweg-Nijman; Thomas Vulsma; Wilhelmina H Stokvis-Brantsma; Catrienus W Rouwé; H Maarten Reeser; Willem-Jan Gerver; Jos J Gosen; Ciska Rongen-Westerlaken; Stenvert L S Drop Journal: J Clin Endocrinol Metab Date: 2003-03 Impact factor: 5.958
Authors: Kitt Falk Petersen; Elif Arioglu Oral; Sylvie Dufour; Douglas Befroy; Charlotte Ariyan; Chunli Yu; Gary W Cline; Alex M DePaoli; Simeon I Taylor; Phillip Gorden; Gerald I Shulman Journal: J Clin Invest Date: 2002-05 Impact factor: 14.808
Authors: Dorothy I Shulman; Allen W Root; Frank B Diamond; Barry B Bercu; Richard Martinez; Robert J Boucek Journal: J Clin Endocrinol Metab Date: 2003-09 Impact factor: 5.958
Authors: Angela E Lin; Craig T Basson; Elizabeth Goldmuntz; Pilar L Magoulas; Deborah A McDermott; Donna M McDonald-McGinn; Elspeth McPherson; Colleen A Morris; Jacqueline Noonan; Catherine Nowak; Mary Ella Pierpont; Reed E Pyeritz; Alan F Rope; Elaine Zackai; Barbara R Pober Journal: Genet Med Date: 2008-07 Impact factor: 8.822
Authors: E Gómez-Guzmán; M D Cañete; R Valle-Martos; R Cañete; M Valle; L Jiménez-Reina; J Caballero-Villarraso Journal: Front Pediatr Date: 2018-06-19 Impact factor: 3.418